Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Yong Won Choi, Jin-Hyuk Choi
Korean J Intern Med. 2017;32(3):422-428.   Published online 2017 Mar 30     DOI: https://doi.org/10.3904/kjim.2016.190
Citations to this article as recorded by Crossref logo
The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients
Adam Szpechcinski, Mateusz Florczuk, Katarzyna Duk, Aneta Zdral, Stefan Rudzinski, Maciej Bryl, Grzegorz Czyzewicz, Piotr Rudzinski, Wlodzimierz Kupis, Emil Wojda, Dorota Giedronowicz, Renata Langfort, Aleksander Barinow-Wojewodzki, Tadeusz Orlowski, Joan
Cellular and Molecular Life Sciences.2019; 76(18): 3641.     CrossRef